Results(4523)
Study protocol objective 2_feasibility assessement: Comparative effectiveness and safety studies using the target trial emulation and estimand frameworks (TARGET-EU-FA)
Belgium
Denmark
Finland
Greece
Italy
Netherlands
Spain
United Kingdom
EU PAS number:
EUPAS1000000791
First published:
09/12/2025
Study
Finalised
Studies on tissue specific carcinogenicity and on metabolism of N-nitrosamines (SC05 to FWC EMA/2020/46/TDA/L1.02 – ROC38))
Germany
EU PAS number:
EUPAS1000000819
First published:
08/12/2025
Study
Planned
Bordeaux PharmacoEpi, University of Bordeaux
France
First published:
08/12/2025
Institution
Educational Institution
Hospital/Clinic/Other health care facility
Not-for-profit
ENCePP partner
VAC4EU Postauthorisation Safety Study of BIMERVAX® Vaccine in Europe
Spain
EU PAS number:
EUPAS1000000321
First published:
08/12/2025
Study
Planned
Impact of EU label changes and pregnancy prevention programme for medicinal products containing valproate and related substances: risk awareness and adherence (ValproateRiskAware)
Belgium
Denmark
Greece
Latvia
Netherlands
Portugal
Slovenia
Spain
EU PAS number:
EUPAS32405
First published:
08/12/2025
Study
Finalised
Impact of EU label changes and revised pregnancy prevention programme for oral retinoid containing medicinal products: risk awareness and adherence (RetinoidRiskAware)
Belgium
Denmark
Greece
Latvia
Netherlands
Portugal
Slovenia
Spain
EU PAS number:
EUPAS32408
First published:
08/12/2025
Study
Finalised
NO LONGER EXISTS - Odense Pharmacoepidemiological Database
First published:
05/12/2025
Denmark
Data source
Human
Administrative healthcare records (e.g., claims)
Post-authorisation Safety Study of Rimegepant in Patients with Migraine and History of Cardiovascular Disease in European Countries
Denmark
Netherlands
Spain
United Kingdom
EU PAS number:
EUPAS103990
First published:
05/12/2025
Study
Planned
CABFIDENCE: Global Real-World Evidence Cohort Study to evaluate Utilization, Clinical and Patient-Reported Outcomes among CAB+RPV LA users (224047)
Australia
Canada
France
Germany
Italy
Japan
Korea, Republic of
Portugal
Spain
Taiwan
United Kingdom
United States
EU PAS number:
EUPAS1000000616
First published:
05/12/2025
Study
Planned
Prospective Observational Non-interventional Study to Describe Characteristics and Management of Patients With Giant Cell Tumor of Bone Treated With XGEVA and Its Use in Routine Clinical Practice in France (20150360)
France
EU PAS number:
EUPAS21542
First published:
05/12/2025
Study
Ongoing
Baricitinib Drug Utilisation Study: Assessment of Effectiveness of New Recommendations for Use Based on Secondary Data Sources in France, Germany, The Netherlands, and Sweden (I4V-MC-B038)
France
Germany
Netherlands
Sweden
EU PAS number:
EUPAS104431
First published:
05/12/2025
Study
Planned
Post-authorisation safety study (PASS): observational cohort study of PAH patients newly treated with either UPTRAVI (selexipag) or any other PAH-specific therapy, in clinical practice (EXPOSURE)
Austria
Belgium
Canada
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Ireland
Italy
Lithuania
Netherlands
Poland
Portugal
Russian Federation
Slovakia
Spain
Sweden
Switzerland
United Kingdom
EU PAS number:
EUPAS19085
First published:
05/12/2025
Study
Ongoing
VAC4EU Postauthorisation Effectiveness Study of BIMERVAX® Vaccine in Europe
Spain
EU PAS number:
EUPAS1000000337
First published:
05/12/2025
Study
Planned
Prospective Study to Assess Usage, Adherence, Effectiveness of Cabotegravir LA for Pre-Exposure Prophylaxis in the United States in the OPERA Cohort (219844)
United States
EU PAS number:
EUPAS1000000165
First published:
05/12/2025
Study
Ongoing
ContrAceptive Research on E4 – Health Effects on eveRyday wellbeing (CARE4HER): A post-authorisation, observational, single-arm, open-label study to evaluate health-related quality of life using the Sociedad Española de Contracepción Quality of Life Questionnaire in women prescribed estetrol (14.2 mg)/ drospirenone (3 mg) for contraception.
Germany
Hungary
Italy
Poland
EU PAS number:
EUPAS106503
First published:
05/12/2025
Study
Finalised
NN8640-4515 A multi-national, multi-centre, prospective, single-arm, observational, non-interventional post-authorisation safety study to investigate long-term safety of Sogroya® (somapacitan) in adults with growth hormone deficiency (AGHD) under routine clinical practice
Australia
Brazil
France
Germany
Japan
Saudi Arabia
Slovenia
United Kingdom
United States
EU PAS number:
EUPAS104526
First published:
05/12/2025
Study
Ongoing
TAK-555-5002: Observational Study to Assess Maternal and Fetal Outcomes Following Exposure to Prucalopride during Pregnancy
United States
EU PAS number:
EUPAS41866
First published:
04/12/2025
Study
Ongoing
Clinical Benefit of Bulevirtide Therapy in Adult Patients With Chronic Hepatitis Delta Compared to a Historical Control Group Receiving Standard of Care
Austria
Belgium
France
Germany
Greece
Italy
Netherlands
Romania
Spain
Sweden
United Kingdom
United States
EU PAS number:
EUPAS1000000463
First published:
04/12/2025
Study
Ongoing
Long-term, Non-interventional Study of Recipients of Tecartus for Treatment of Adult Patients With Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL) or Adult Patients With R/R B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
Austria
Canada
Czechia
France
Germany
Israel
Italy
Netherlands
Poland
Portugal
Spain
Switzerland
United Kingdom
United States
EU PAS number:
EUPAS45813
First published:
04/12/2025
Study
Ongoing
Impact of EU label changes and revised pregnancy prevention programme for oral retinoid containing medicinal products: utilization and prescribing trends
Denmark
France
Italy
Netherlands
Spain
EU PAS number:
EUPAS31095
First published:
04/12/2025
Study
Finalised
Comparative effectiveness and safety studies using the target trial emulation and estimand frameworks (TARGET-EU)
Belgium
Denmark
Finland
Italy
Netherlands
Norway
Spain
United Kingdom
EU PAS number:
EUPAS1000000539
First published:
04/12/2025
Study
Planned
Description of international collaboration in the area of medicines use and effects in COVID-19 affected pregnancies (CONSIGN-International))
Belgium
Canada
Denmark
Finland
Germany
Iceland
Italy
Netherlands
Norway
Saudi Arabia
Spain
Sweden
Switzerland
United Kingdom
United States
EU PAS number:
EUPAS40317
First published:
04/12/2025
Study
Finalised
CONSIGN study: COVID-19 infection and medicines in pregnancy - a multinational registry based study
Denmark
France
Germany
Italy
Norway
Spain
Sweden
United Kingdom
EU PAS number:
EUPAS39438
First published:
04/12/2025
Study
Finalised
Impact of EU label changes and revised pregnancy prevention programme for medicinal products containing valproate: utilisation and prescribing trends
Denmark
Italy
Netherlands
Spain
United Kingdom
EU PAS number:
EUPAS31001
First published:
04/12/2025
Study
Finalised
Impact of biologics on inhaled corticosteroids reduction (MOON LIGHT)
Argentina
Belgium
Brazil
Bulgaria
Canada
Colombia
Denmark
Estonia
France
Greece
India
Ireland
Italy
Japan
Korea, Republic of
Kuwait
Mexico
Norway
Poland
Portugal
Saudi Arabia
Singapore
Spain
Taiwan
United Arab Emirates
United Kingdom
United States
EU PAS number:
EUPAS1000000855
First published:
04/12/2025
Study
Ongoing
Molecular profiling of tissue samples from patients who received a Kite-manufactured gene-modified cell therapy and have developed a secondary malignancy of T-cell origin
European Union
United Kingdom
EU PAS number:
EUPAS1000000769
First published:
04/12/2025
Study
Planned
Post-marketing Surveillance (PMS) on long term use of Ofev Capsules in Systemic Scleroderma associated Interstitial Lung Disease (SSc-ILD) in Japan (PMS for Ofev (SSc-ILD))
Japan
EU PAS number:
EUPAS32905
First published:
04/12/2025
Study
Ongoing
Post-Authorization Active Surveillance Safety Study Using Secondary Data to Monitor Real World Safety of mRESVIA (mRNA-1345) for Respiratory Syncytial Virus (RSV) in Europe
European Union
United Kingdom
EU PAS number:
EUPAS1000000732
First published:
04/12/2025
Study
Ongoing
INOtuzumab Treatment Retrospective Analysis for Navigating tranSITion to CD19 CAR-T. Real-world (RWD) treatment patterns and clinical outcomes in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukaemia (ALL) treated with inotuzumab-ozogamicin (InO) as bridge to chimeric antigen receptor T-cell (CAR-T) therapy in Spain, the United Kingdom (UK) and the United States (US) (INO-TRANSIT)
Spain
United Kingdom
United States
EU PAS number:
EUPAS1000000118
First published:
04/12/2025
Study
Ongoing
Periodic Knowledge, Attitudes, and Behavior (KAB) Survey of Patients and/or Caregivers to Assess Understanding of the Risks with the BKEMV™ Risk Evaluation and Mitigation Strategy (REMS) (20240214)
United States
EU PAS number:
EUPAS1000000368
First published:
04/12/2025
Study
Planned
Post-marketing study to assess the risk of intussusception after immunization with GlaxoSmithKline (GSK) Biologicals’ oral live-attenuated human rotavirus vaccine in infants less than 1 year old in Latin America (212329)
Argentina
Colombia
Dominican Republic
Honduras
Mexico
Panama
EU PAS number:
EUPAS1000000701
First published:
04/12/2025
Study
Planned
A Non-interventional Multi-country Cohort Study to Assess the Safety of EVUSHELD™ (Tixagevimab/Cilgavimab) During Pregnancy (O-STEREO Study)
Canada
France
United States
EU PAS number:
EUPAS49565
First published:
04/12/2025
Study
Discontinued
Xarelto Paediatric VTE PASS Drug Utilization Study: An observational, longitudinal, multi-source drug utilization safety study to evaluate the drug use patterns and safety of rivaroxaban oral suspension in children under two years with venous thromboembolism (XAPAEDUS)
Denmark
France
Spain
Sweden
EU PAS number:
EUPAS46800
First published:
04/12/2025
Study
Planned
Exposure to SSRI/SNRI and depression in pregnancy and long-term childhood outcomes: the effect of modifying factors
Belgium
Croatia
Denmark
Finland
France
Germany
Ireland
Italy
Malta
Netherlands
Poland
Réunion
Spain
Sweden
Switzerland
Ukraine
United Kingdom
EU PAS number:
EUPAS43416
First published:
04/12/2025
Study
Ongoing
DARWIN EU® Effectiveness of Human Papillomavirus Vaccines (HPV) to prevent cervical cancer
Germany
Spain
United Kingdom
EU PAS number:
EUPAS1000000080
First published:
03/12/2025
Study
Finalised
SLC6A1-NDD PROSPECTIVE LONGITUDINAL NATURAL HISTORY STUDY (SPIRIT)
Denmark
European Union
France
Germany
Italy
Spain
United Kingdom
United States
EU PAS number:
EUPAS1000000861
First published:
01/12/2025
Study
Planned
Norwegian Linked Health registry at University of Oslo
First published:
28/11/2025
Norway
Data source
Human
Birth registry
Death registry
Disease registry
Hospital inpatient records
Hospital outpatient visit records
Pharmacy dispensing records
Population registry
Primary care medical records
Vaccination registry
Hillel Yaffe -Kineret
First published:
28/11/2025
Israel
Data source
Human
Emergency care discharge records
Hospital inpatient records
Hospital outpatient visit records
Other
Shamir Governmental Medical Center, part of Nationwide network (Kineret)
First published:
28/11/2025
Israel
Data source
Human
Emergency care discharge records
Hospital inpatient records
Hospital outpatient visit records
Other
Tzafon Governmental Medical Center, part of Nationwide network (Kineret)
First published:
28/11/2025
Israel
Data source
Human
Emergency care discharge records
Hospital inpatient records
Hospital outpatient visit records
OtherCompare data sources